Breast Cancer Clinical Trial
A Study Of PF-06263507 In Patients With Advanced Solid Tumors
Summary
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.
Performance Status of 0 or 1.
Adequate bone marrow, kidney, liver, and heart function.
Exclusion Criteria:
Brain metastases requiring steroids.
Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
Active bacterial, fungal or viral infection.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Boston Massachusetts, 02115, United States
Boston Massachusetts, 02215, United States
Detroit Michigan, 48201, United States
Philadelphia Pennsylvania, 19111, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.